Articles tagged "HLA antibodies"

2022 American Transplant Congress
Poor Outcomes in Patients with Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions
K. Wu¹, D. Schmidt¹, C. Lopez del Moral¹, Q. Zhang¹, F. Halleck¹, M. G. Naik¹, N. Lachmann², B. Rudolph³, K. Budde¹
¹Department of Nephrology, Charite Campus Mitte, Berlin, Germany, ²Institut für Transfusionsmedizin, Charite Virchow Klinikum, Berlin, Germany, ³Institut für Pathologie, Charite Campus Mitte, Berlin, Germany
*Purpose: Banff classification is an accepted diagnostic tool, but also used as a tool to define endpoints in clinical trials. There is a need to…
2022 American Transplant Congress
“ABO-Adjusted CPRA”: A Unified Metric for Immunologic Compatibility in Kidney Transplantation
L. Gragert¹, M. Kadatz², J. Alcorn³, D. Stewart³, D. Chang², J. Gill², R. Liwski⁴, H. Gebel⁵, E. Kransdorf⁶, J. Gill², J. Lan²
¹Tulane University, New Orleans, LA, ²University of British Columbia, Vancouver, BC, Canada, ³UNOS, Richmond, VA, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Emory University, Atlanta, GA, ⁶Cedars-Sinai, Beverly Hills, CA
*Purpose: Implementation of the kidney allocation system in 2014 greatly reduced access disparity due to HLA sensitization. To address persistent disparities among both candidate cPRA…
2022 American Transplant Congress
Bone Marrow Resident Long-Lived Plasma Cells as Source of Chronic Donor-Specific Antibodies
M. Muckenhuber, S. Pichler, A. M. Weijler, T. Wekerle
Dept. of General Surgery, Div. of Transplantation, Medical University of Vienna, Vienna, Austria
*Purpose: The importance of bone marrow resident plasma cells for long-lasting humoral immunity has been highlighted in several models for vaccination and infectious diseases. To…
2021 American Transplant Congress
Transplant Glomerulopathy in the Absence of Donor-specific HLA Antibodies: Risk Factors, Histopathological Features and Graft Outcome
A. Senev, E. Van Loon, M. Emonds, M. Naesens
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: Transplant glomerulopathy (TG) is established as a hallmark of chronic antibody-mediated rejection in kidney transplant patients with donor-specific HLA antibodies (HLA-DSA). The clinical importance…
2021 American Transplant Congress
The Use of Donor Derived Cell Free DNA in Children to Monitor Therapy of Kidney Rejection
A. Al-Uzri, M. Wright, K. Clark, R. Jenkins
Oregon Health & Science Univ, Portland, OR
*Purpose: Elevated donor-derived cell-free DNA (dd-cfDNA) in the presence of HLA donor-specific antibodies (DSA) are shown to correlate with acute antibody-mediated rejection (AMR) in adult…
2021 American Transplant Congress
High Donor-Derived Cell-Free DNA Levels Predict Development of De Novo HLA Donor-Specific Antibodies After Kidney Transplantation – Data from the ADMIRAL Study
G. Gupta¹, T. Alhamad², V. Bowers³, I. Moinuddin¹, S. Ghosh⁴, J. Zeng⁴, E. Stites⁵, A. Pai⁶, J. S. Bromberg⁷, S. Anand⁸
¹Virginia Commonwealth University, Richmond, VA, ²Washington University in St. Louis, St. Louis, MO, ³Tampa General Hospital, Tampa, FL, ⁴CareDx, Brisbane, CA, ⁵University of Colorado, Aurora, CO, ⁶University of Texas McGovern Medical School, Houston, TX, ⁷University of Maryland School of Medicine, Baltimore, MD, ⁸Intermountain Medical Center, Murray, UT
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) as a marker of injury can serve to quantify subclinical inflammation and molecular injury. As the release of graft genomic…
2021 American Transplant Congress
Bortezomib for Antibody-Mediated Rejection of Renal Transplant in Youth
L. Galea, J. Hewlett, J. Savant, S. Lopez, S. Amaral, B. Viteri
The Children’s Hospital of Philadelphia, Philadelphia, PA
*Purpose: The purpose of the study was to examine preliminary efficacy and tolerability of bortezomib, a protease inhibitor, in treatment-refractory antibody mediated rejection (AMR) in…
2021 American Transplant Congress
Prospective Intensive Monitoring for Anamnestic DSA Responses Allows Near Elimination of Early Clinical AMR
M. McGowan¹, A. Bickenbach¹, A. R. Shields², R. R. Alloway¹, P. Brailey¹, E. Portwood¹, C. Alquist¹, A. Christianson¹, B. Abu Jawdeh¹, M. Cuffy¹, J. Kremer², S. Bumb¹, A. Govil¹, M. Anand¹, T. Kaur¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: Anamnestic donor specific antibody (aDSA) responses can result in severe, graft threatening antibody-mediated rejection (AMR). We hypothesized that intensive DSA monitoring (IDM) for aDSA…
2021 American Transplant Congress
Membrane versus Centrifuge‑Based Therapeutic Plasma Exchange to Treat Antibody-Mediated Rejection in Kidney Transplantation
P. Maggiani¹, J. C. Ramirez Valdestino¹, J. H. Cano Cervantes¹, O. D. Díaz Avedaño¹, G. García Castillo¹, M. C. Oseguera Vizcaíno², M. A. Covarrubias², M. Matías Carmona¹, D. F. Ovando Morga¹, G. Ramirez Ramirez¹, V. D. Lebrija Córdoba¹, S. Hernandez Estrada¹
¹Transplantation, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico, ²Transplantation, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico
*Purpose: Therapeutic plasma exchange (TPE) is either performed using a highly permeable filter with standard multifunctional renal replacement equipment (mTPE) or a centrifugation device (cTPE).…
2021 American Transplant Congress
Is There a Role for Donor-Specific Antibody Testing in Simultaneous Liver-Kidney Transplantation? A Single Center Analysis of Outcomes
A. Das, A. Barbetta, D. Remulla, C. Goldbeck, T. Maw, J. Kim
University of Southern California, Los Angeles, CA
*Purpose: Simultaneous liver-kidney transplantation (SLKT) has grown exponentially since its conception in the 1960’s. The role for donor specific antibody (DSA) testing in SLKT is…